Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Long-Term Outcome of Chronic Phase Chronic Myeloid Leukemia Patients Treated with Nilotinib Front-Line

Franck E Nicolini, MDPhD, Vincent Alcazer, MD, Pascale Cony-Makhoul, MD, Stephanie Dulucq, PharmD, PhD, Sandrine Hayette, PhD, Stephane Morisset, BioStat, Jean-Michel Cayuela, PharmD, PhD, Marie-Pierre Fort, PhD, Christophe Bouvier, CRA, Clemence Deteix-Santana, MD, Etienne Lengline, MD, Delphine Rea, MDPhD, Francois-Xavier Mahon, MD PhD, Gabriel Etienne, MD PhD

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-139921

Published: 2020

Journal Articles

Very Long-Term Follow-up (> 80 months) of Imatinib (IM) First-Line for Chronic Phase (CP) CML Patients

Franck E. Nicolini, MD PhD, Marie Balsat, MD, Maud Lekieffre, MD, Vincent Alcazer, MD, Hélène Labussière-wallet, MD, Sarah Huet, PharmD, PhD, Sandrine Hayette, Stéphanie Dulucq, PharmD, PhD, Stéphane Morisset, Stat, Jeremy Ruby, CRA, Isabelle Tigaud, MD, Marie-Pierre Fort, CRA, Mael Heiblig, MD, Rémi Chapelon, CRA, Madeleine Etienne, CRA, Mohamad Sobh, PharmD, Francois-Xavier Mahon, MD PhD Professor, Mauricette Michallet, MD PhD, Gabriel Etienne, MD PhD

Blood (2015) 126 (23): 2774.

https://doi.org/10.1182/blood.V126.23.2774.2774

Published: 2015

Journal Articles

ELN 2013 Response Status Criteria: Relevance For De Novo imatinib Chronic Phase Chronic Myeloid Leukemia Patients?

Gabriel Etienne, MD, PHD, Stephanie Dulucq, MD, Axelle Lascaux, MD, Anna Schmitt, MD, Audrey Bidet, Marie-Pierre Fort, Eric Lippert, Caroline Bureau, Didier Adiko, MD, Sandrine Hayette, Josy Reiffers, MD, Franck E. Nicolini, MD PhD, Francois-Xavier Mahon, MD, PhD

Blood (2013) 122 (21): 4029.

https://doi.org/10.1182/blood.V122.21.4029.4029

Published: 2013

Journal Articles

CML Patients Show Sperm Alterations At Diagnosis That Are Not Improved On Tyrosine Kinase Inhibitor Treatment

Franck E. Nicolini, MD, PhD, Françoise Huguet, Hélène Labussière-Wallet, MD, Yann Guillermin, MD, Madeleine Etienne, CRA, Marie-Pierre Fort, CRA, Isabelle Tigaud, MD, Sandrine Hayette, Stephane Morisset, Stat., Mohamad Sobh, Pharm.M., Fiorenza Barraco, MD, Mauricette Michallet, MD, PhD, Myriam Daudin, MD, Volcy Soula, MD, Sandrine Giscard d'Estaing, MD, Gabriel Etienne, MD, PhD

Blood (2012) 120 (21): 1669.

https://doi.org/10.1182/blood.V120.21.1669.1669

Published: 2012

Journal Articles

The Month Three Major Molecular Response in Chronic Phase Chronic Myeloid Leukemia on imatinib 400 , Nilotinib and Dasatinib Is a Major Prognostic Factor for Failure-Free and Progression-Free Survival

Franck E Nicolini, MD, PhD, Sandrine Hayette, PhD, Helene Labussiere, MD, PhD, Madeleine Etienne, CRA, Marie-Pierre Fort, Elodie Gadolet, CRA, Isabelle Tigaud, MD, Kaddour Chabane, Eric Lippert, MD, Mohamad Sobh, Pharm.M., Stephanie Dulucq, MD, Stephane Morisset, Stat., Mauricette Michallet, Francois-Xavier Mahon, MD, PhD, Gabriel Etienne, MD, PhD

Blood (2011) 118 (21): 1684.

https://doi.org/10.1182/blood.V118.21.1684.1684

Published: 2011

Journal Articles

Interferon Alpha Alone Is Able to Cure Chronic Myeloid Leukemia In a Small Subset of Patients Despite the Persistence of Leukemic Cells: Experience of Long Follow up After Treatment Discontinuation

Francois-Xavier Mahon, MD, PhD, Marie-Pierre Fort, Gabriel Etienne, Gerald Marit, Noel Milpied, Arnaud Pigneux, MD, PhD, Pascale Cony-Makhoul, Josy Reiffers

Blood (2010) 116 (21): 2299.

https://doi.org/10.1182/blood.V116.21.2299.2299

Published: 2010

Journal Articles

Loss of the Y Chromosome in Philadelphia-Positive Cells Predicts a Poor Response of CML Patients to Imatinib Mesylate Therapy.

Eric Lippert, Sophy Laibe, Marie-Joelle Mozziconacci, Carine Gervais, Stéphane Girault, Nathalie Gachard, Isabelle Tigaud, Nicole Dastugue, Francoise Huguet, Marie-Pierre Fort, Virginie Eclache, Francois-Xavier Mahon

Blood (2008) 112 (11): 2117.

https://doi.org/10.1182/blood.V112.11.2117.2117

Published: 2008

NARROW

Long-Term Outcome of Chronic Phase Chronic Myeloid Leukemia Patients Treated with Nilotinib Front-Line

Very Long-Term Follow-up (> 80 months) of Imatinib (IM) First-Line for Chronic Phase (CP) CML Patients

ELN 2013 Response Status Criteria: Relevance For De Novo imatinib Chronic Phase Chronic Myeloid Leukemia Patients?

CML Patients Show Sperm Alterations At Diagnosis That Are Not Improved On Tyrosine Kinase Inhibitor Treatment

The Month Three Major Molecular Response in Chronic Phase Chronic Myeloid Leukemia on imatinib 400 , Nilotinib and Dasatinib Is a Major Prognostic Factor for Failure-Free and Progression-Free Survival

Interferon Alpha Alone Is Able to Cure Chronic Myeloid Leukemia In a Small Subset of Patients Despite the Persistence of Leukemic Cells: Experience of Long Follow up After Treatment Discontinuation

Loss of the Y Chromosome in Philadelphia-Positive Cells Predicts a Poor Response of CML Patients to Imatinib Mesylate Therapy.

Email alerts

ASH Publications

American Society of Hematology

Long-Term Outcome of Chronic Phase Chronic Myeloid Leukemia Patients Treated with Nilotinib Front-Line

Very Long-Term Follow-up (> 80 months) of Imatinib (IM) First-Line for Chronic Phase (CP) CML Patients

ELN 2013 Response Status Criteria: Relevance For De Novo imatinib Chronic Phase Chronic Myeloid Leukemia Patients?

CML Patients Show Sperm Alterations At Diagnosis That Are Not Improved On Tyrosine Kinase Inhibitor Treatment

The Month Three Major Molecular Response in Chronic Phase Chronic Myeloid Leukemia on imatinib 400 , Nilotinib and Dasatinib Is a Major Prognostic Factor for Failure-Free and Progression-Free Survival

Interferon Alpha Alone Is Able to Cure Chronic Myeloid Leukemia In a Small Subset of Patients Despite the Persistence of Leukemic Cells: Experience of Long Follow up After Treatment Discontinuation

Loss of the Y Chromosome in Philadelphia-Positive Cells Predicts a Poor Response of CML Patients to Imatinib Mesylate Therapy.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only